Does Bicara Therapeutics Inc. ( BCAX ) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?
The consensus price target hints at an 187.7% upside potential for Bicara Therapeutics Inc. (BCAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in ...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire ...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Relay Therapeutics ( NASDAQ:RLAY ) , Bicara Therapeutics ( NASDAQ:BCAX )
CAMBRIDGE, Mass., June 11, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. RLAY, a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, ...
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Median DOR of 21.7 months with 80% of responders achieving a deep response ( ≥80% tumor shrinkage ...
Bicara Therapeutics Shares Sink Over 43% On Friday - Bicara Therapeutics ( NASDAQ:BCAX )
Bicara shares plunged over 43% after interim trial data for ficerafusp alfa showed mixed results. Despite a 64% response rate in HPV-negative patients, investors reacted negatively to the lack of mature overall survival
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook - Bicara Therapeutics ( NASDAQ:BCAX ) , BloomZ ( NASDAQ:BLMZ )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Friday. The Dow traded down 0.70% to 41,566.04 while the NASDAQ fell 1.12% to 18,713.37. The S&P 500 also fell, dropping, 0.87% to 5,791.25. Utilities shares fell by just 0.2% on Friday.
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results - Bicara Therapeutics ( NASDAQ:BCAX ) , BloomZ ( NASDAQ:BLMZ )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Friday. The Dow traded down 0.70% to 41,566.04 while the NASDAQ fell 1.12% to 18,713.37. The S&P 500 also fell, dropping, 0.87% to 5,791.25. Real estate shares fell by just 0.1% on Friday.
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Deckers Outdoor ( NYSE:DECK ) , Bicara Therapeutics ( NASDAQ:BCAX )
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Friday. Shares of Ross Stores, Inc. ROST fell sharply in today's pre-market trading after the company issued second-quarter EPS guidance below estimates.
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting - Bicara Therapeutics ( NASDAQ:BCAX )
BOSTON, May 22, 2025 ( GLOBE NEWSWIRE ) -- Bicara Therapeutics Inc.
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday - Bicara Therapeutics ( NASDAQ:BCAX ) , Caterpillar ( NYSE:CAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Endava plc DAVA price target from $13 to $17. Needham analyst John Todaro maintained a Buy ...
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting ...
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting
BOSTON, April 23, 2025 ( GLOBE NEWSWIRE ) -- Bicara Therapeutics Inc. ( Nasdaq: BCAX ) , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b ...
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Bicara Therapeutics ( NASDAQ:BCAX ) , Amkor Tech ( NASDAQ:AMKR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in ...
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - Bicara Therapeutics ( NASDAQ:BCAX )
BOSTON, March 25, 2025 ( GLOBE NEWSWIRE ) -- Bicara Therapeutics Inc.
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 ( GLOBE NEWSWIRE ) -- Bicara Therapeutics Inc. ( Nasdaq: BCAX ) , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead ...
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium - Bicara Therapeutics ( NASDAQ:BCAX )
BOSTON, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Bicara Therapeutics Inc.
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
BOSTON, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Bicara Therapeutics Inc. ( Nasdaq: BCAX ) , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the Phase 1/1b dose ...
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Alvotech ( NASDAQ:ALVO ) , Beasley Broadcast Group ( NASDAQ:BBGI )
Shares of Versus Systems Inc. VS rose sharply in today's pre-market trading after the company announced expansion into the Brazilian market as part of its strategy to grow its international footprint. Versus Systems shares jumped 71.2% to $3.39 in the pre-market trading session.
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Alvotech ( NASDAQ:ALVO ) , Beasley Broadcast Group ( NASDAQ:BBGI )
Shares of Versus Systems Inc. VS rose sharply in today's pre-market trading after the company announced expansion into the Brazilian market as part of its strategy to grow its international footprint. Versus Systems shares jumped 71.2% to $3.39 in the pre-market trading session.
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - AppLovin ( NASDAQ:APP ) , Bicara Therapeutics ( NASDAQ:BCAX )
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday. Shares of BioAge Labs, Inc. BIOA fell sharply in today's pre-market trading after the company announced discontinuation of STRIDES Phase 2 clinical trial evaluating Azelaprag in combination with ...
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Abbott Laboratories ( NYSE:ABT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer analyst Suraj Kalia initiated coverage on Abbott Laboratories ABT with an Outperform rating and ...
